/

Actinium Pharmaceuticals, Inc.

ATNM US

ATNM USActinium Pharmaceuticals, Inc.

United States Composite

6.83

USD

+0.23

(+3.48%)

-1.92EPS Dil.

-3.56P/E

187.23MMarket Cap

Next Earnings

November 2

Dividend Date

August 11

Held by Insiders

2.10%

Held by Institutions

25.88%

Short % of Float

7.45%

YTD Yield

-38.64%

3Y Yield

-31.30%

Capital Structure

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

ST Debt

LT Borrowings

- -

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

243

200

162

Working Capital

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

Total Current Assets

Cash, Cash Equivalents & STI

Accounts Receivable, Net

- -

Inventories

- -

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

Net Income, GAAP

-20.18%

-5.24%

-32.00%

Free Cash Flow

-34.57%

-26.75%

-138.10%

Total Cash Common Dividend

- -

Total Equity

-68.23%

171.62%

-10.81%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

2022

- -

2023

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.29

-0.25

-0.30

-0.36

-1.20

2022

-0.23

-0.33

-0.38

-0.42

-1.37

2023

-0.43

-0.58

-0.49

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Sandesh C. Seth M.B.A., M.S.
Full Time Employees: 49
Sector: Healthcare
Industry: Biotechnology
Address: 275 Madison Avenue New York NY United States 10016
CIK: 0001388320
Website: www.actiniumpharma.com
Business: Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.

Company Description

CEO: Mr. Sandesh C. Seth M.B.A., M.S.
Full Time Employees: 49
Sector: Healthcare
Industry: Biotechnology
Address: 275 Madison Avenue New York NY United States 10016
CIK: 0001388320
Website: www.actiniumpharma.com
Business: Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.